18407 Improvement of short-term outcome of mild to moderate atopic dermatitis using a combination treatment of crisaborole ointment 2% and a concomitant topical cortiscosteroid over a 8 week period

Background: Atopic dermatitis (AD) also known as atopic eczema is a chronic inflammatory skin disease that is characterized by intense itching and recurrent eczematous lesions. Although it most often starts in infancy and affects two of ten children, it is also highly prevalent in adults. Current topical treatments for AD have not changed in over 15 years and are associated with safety concerns. In AD, overactivity of phosphodiesterase 4 (PDE4), leads to inflammation and disease exacerbation. Combination therapy is known to be superior to monotherapy and is commonly used in other skin diseases. It has been shown that the addition of a corticosteroid (triamcinolone acetonide ointment, 0.1%) to other therapies have been shown to improve the efficacy and decrease the skin irritation normally associated with other therapies alone. By combining medications with a different mechanism of action and safety profile, efficacy can be enhanced and/or safety improved. This study (n = 16) is of the efficacy and safety of crisaborole ointment 2% when combined with a topical steroid (triamcinolone acetonide ointment, 0.1%) for the treatment of mild to moderate atopic dermatitis in subjects 2–79 years of age. Subjects were randomized to crisaborole alone versus combination treatment.